Increases in hepatic cytochrome P450 content have been observed in female rats administered limonene (isomer unspecified; 40 mg/kg bw/d for 3 days) by intraperitoneal injection *(Austin et al., 1988) and in rats administered 5% dlimonene in the diet for 2 weeks *(Maltzman et al., 1991). Increased epoxide hydratase activity was observed in rats administered 1% or 5% d-limonene in the diet for 2 weeks *(Maltzman et al., 1991). Increases in phase II enzymes (glutathionyltransferase and UDPglucuronyltransferase) during the exposure of rats to 5% limonene in food have also been described *(Maltzman, 1991). Increased relative liver weight (from 5 to 20 times) has been observed in rats administered d-limonene at a dose of 75300 mg/kg bw, at 300 mg/kg bw, the increase was significant *(Kanerva et al., 1987). In cats, infusion of 97% dlimonene into the bile system to dissolve gallstones caused acute and chronic inflammatory changes *(Schenk et al., 1980).
10.4Long-term exposure 10.4.1Subchronic exposure
Peroral administration of d-limonene to rats at a dose of 400 mg/kg bw for 30 d resulted in a 2030% increase in the amount and activity of different liver enzymes (cytochrome P450, cytochrome b5, aminopyrine demethylase, and aniline hydroxylase), increased relative liver weight, and decreased cholesterol levels *(Ariyoshi et al., 1975). Administration of d-limonene (0, 2, 5, 10, 30, and 75 mg/kg bw/d) by gavage to groups of 10 male rats, 5 d/week for 13 weeks *(Webb et al., 1989), resulted in the pathological formation of granular casts at the outer zone of the renal medulla. The no-observed-effect level (NOEL), based upon histological examination of the kidneys, was considered to be 5 mg/kg bw/d. The LOEL for increased liver and kidney weight was 75 mg/kg bw/d, the highest dose tested. The NOEL for effects in the liver was 10 mg/kg bw; the no-observed-adverse-effect level (NOAEL) for effects in the liver was 30 mg/kg bw/d. Linear regression analysis revealed a dose-related trend in the increased relative weights of the kidney and liver at 30 and 75 mg/kg bw/d. No histopathological changes were observed in the liver in these two studies. The amount and activity of different liver enzymes were not investigated, and thus the increase in relative liver weight may be due to enzyme induction. It is considered that the observed effects in the liver are probably signs of a physiological adaptation (Karlberg & Lindell, 1993).
10.4.2Chronic exposure and carcinogenicity
The oral administration of dlimonene (0.4, 1.2, or 3.6 ml/kg bw/d) to dogs for 6 months caused nausea and vomiting *(Tsuji et al., 1975a). A 35% increase in alkaline phosphatase and cholesterol in serum and slightly increased total and relative liver weights were observed in dogs after peroral administration of dlimonene at a dose of 1.2 ml/kg bw/d for 6 months (about 1000 mg/kg bw/d) *(Webb et al., 1990).
In a 2y study, dlimonene was administered (per os) 5 d/week to groups of 50 F344/N rats (0, 75, or 150 mg/kg bw/d to males, and 0, 300, or 600 mg/kg bw/d to females) and B6C3F mice (0, 250, or 500 mg/kg bw/d to males, and 0, 500, or 1000 mg/kg bw/d to females) (NTP, 1990). Slightly lower body weights were observed for rats in the highdose groups and female mice in the highdose group; however, no clinical symptoms could be related to the administration of d-limonene. For female rats in the highdose group, survival was reduced after 39 weeks (NTP, 1990). There was clear evidence of carcinogenic activity of d-limonene in male rats, based upon a doserelated increase in the incidence of hyperplasia and adenoma/ adenocarcinoma in renal tubular cells. However, there was no evidence of carcinogenicity in female rats or in male and female mice. The carcinogenic response in the kidney of male rats has been linked to a unique renal perturbation involving 2globulin.
To determine whether dlimonene would cause a sustained increase in renal cell proliferation and exhibit promoting activity for the development of renal adenomas in male F344 rats, the animals were administered (by stomach tube) dlimonene (150 mg/kg bw/d) as a promoter 5 d/week for 30 weeks *(Dietrich & Swenberg, 1991). NethylNhydroxyethyl-nitrosamine (500 ppm) (2780 mg/m3) (was used as an initiator in the drinkingwater for 2 weeks. In addition, male 2-globulindeficient rats were exposed in the same manner to determine if the mate rat specific urinary protein 2-globulin is required for dlimonene to cause these effects. Exposure to dlimonene alone caused a significant increase in the number of atypical tubules and atypical hyperplasias in F344 rats, compared with vehicle controls. There was no increase in the incidence of tumours or preneoplastic lesions in the 2globulin deficient rats exposed to dlimonene, whereas a 10fold increase in the incidence of renal adenoma and atypical hyperplasia was observed in F344 rats exposed to d-limonene compared with controls. There was a significant decrease in the incidence of liver tumours in animals exposed to NethylNhydroxyethylnitrosamine and d-limonene, compared with NethylNhydroxyethylnitrosamine exposure alone.
10.5Genotoxicity and related endpoints
On the basis of available data, there is no evidence that dlimonene or its metabolites are genotoxic or mutagenic. Limonene and its epoxides were not mutagenic when tested at concentrations of 0.3 to 3333 g/plate in in vitro assays using different strains of Salmonella typhimurium, in the presence or absence of metabolic activation *(Florin et al., 1980; *Watabe et al., 1981; *Haworth et al., 1983; *Connor et al., 1985; NTP, 1990). dLimonene did not increase the frequency of forward mutation at the TK+/- locus in mouse L5 178Y cells (NTP, 1990), induce cytogenetic damage in Chinese hamster ovary cells *(Anderson et al., 1990), or malignantly transform Syrian hamster embryo cells *(Pienta, 1980). In one in vitro study, following exposure with benzo(a)pyrene, d-limonene (21.9 mol/litre) inhibited the formation of transformed cell colonies in tracheal epithelium isolated from rats *(Steele et al., 1990).
No evidence of mutagenicity was reported in an in vivo spot test with mice, involving the intraperitoneal injection of limonene at 215 mg/kg bw/d on days 911 during gestation *(Fahrig, 1984).
Share with your friends: |